Effects of caffeine on diaphragmatic activity in preterm infants

Pediatr Pulmonol. 2023 Jul;58(7):2104-2110. doi: 10.1002/ppul.26439. Epub 2023 May 5.

Abstract

Background: Caffeine is the first-choice drug for the treatment for apnea of prematurity (AOP) in preterm infants and it has been reported that it improves the diaphragm activity. The aim of this study was to evaluate by ultrasound possible changes in diaphragm contractility and motility induced by caffeine.

Methods: We studied 26 preterm infants with gestational age ≤34 weeks treated with caffeine for the prevention or treatment of AOP. Diaphragmatic ultrasound was performed 15 min (T0 ) before and 60 min (T60 ) after the loading (20 mg/kg) or maintenance (5 mg/kg) dose of caffeine.

Results: Diaphragmatic excursion (DE) and thickness at the end of inspiration (DT-in) and expiration (DT-ex), as well as peak velocity of the excursion at the end of inspiration (DT-in) and expiration (DT-ex) increased after administration of both loading and maintenance dose of caffeine.

Conclusions: Ultrasounds confirmed that caffeine improves the activity of diaphragm in preterm infants improving its thickness, amplitude of excursions, and contraction velocity. These results are consistent with the effectiveness of caffeine in treating AOP and decreasing the risk of failure of noninvasive respiratory support in preterm infants with respiratory distress syndrome (RDS).

Keywords: caffeine; diaphragm; echography; point-of-care; preterm infant; ultrasound.

MeSH terms

  • Apnea / drug therapy
  • Caffeine* / pharmacology
  • Caffeine* / therapeutic use
  • Diaphragm / diagnostic imaging
  • Gestational Age
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Sleep Apnea Syndromes*

Substances

  • Caffeine

Grants and funding